Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating
/ adverse effects
Chemotherapy, Cancer, Regional Perfusion
/ adverse effects
Female
Humans
Liver Neoplasms
/ diagnostic imaging
Male
Melanoma
Melphalan
/ therapeutic use
Middle Aged
Neoplasms, Second Primary
Uveal Neoplasms
/ diagnostic imaging
Uveal melanoma
chemosaturation
hepatic metastases
tumor load
tumor response
Journal
Acta radiologica (Stockholm, Sweden : 1987)
ISSN: 1600-0455
Titre abrégé: Acta Radiol
Pays: England
ID NLM: 8706123
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
pubmed:
27
5
2021
medline:
9
4
2022
entrez:
26
5
2021
Statut:
ppublish
Résumé
Patients with hepatic metastatic uveal melanoma still have a poor outcome. To evaluate overall survival (OS), progression-free survival (PFS), and response predictors in these patients treated with chemosaturation by percutaneous hepatic perfusion with melphalan (CS-PHP). Between June 2015 and March 2020, a total of 29 patients (median age 69.7 years; age range 30-81 years; 60% women; median BMI 25.7 kg/m After the initial CS-PHP, a partial response was observed in 11 patients (41%), stable disease in 12 patients (44%) and progressive disease in 4 patients (15%); two patients died before the response was evaluated. After initial CS-PHP, median OS was 12.9 ± 7.4 months and median PFS was 7.1 ± 7.4 months. OS after one year was 50%. After the second CS-PHP, median PFS was 7.9 ± 5.7 months. Seven patients had a liver tumor burden >25%, associated with a significantly shorter OS (6.0 ± 2.4 vs. 14.1 ± 12.7 months; CS-PHP is a safe and effective treatment for the hepatic metastatic uveal melanoma, especially for patients with a hepatic tumor burden <25%.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with hepatic metastatic uveal melanoma still have a poor outcome.
PURPOSE
OBJECTIVE
To evaluate overall survival (OS), progression-free survival (PFS), and response predictors in these patients treated with chemosaturation by percutaneous hepatic perfusion with melphalan (CS-PHP).
MATERIAL AND METHODS
METHODS
Between June 2015 and March 2020, a total of 29 patients (median age 69.7 years; age range 30-81 years; 60% women; median BMI 25.7 kg/m
RESULTS
RESULTS
After the initial CS-PHP, a partial response was observed in 11 patients (41%), stable disease in 12 patients (44%) and progressive disease in 4 patients (15%); two patients died before the response was evaluated. After initial CS-PHP, median OS was 12.9 ± 7.4 months and median PFS was 7.1 ± 7.4 months. OS after one year was 50%. After the second CS-PHP, median PFS was 7.9 ± 5.7 months. Seven patients had a liver tumor burden >25%, associated with a significantly shorter OS (6.0 ± 2.4 vs. 14.1 ± 12.7 months;
CONCLUSION
CONCLUSIONS
CS-PHP is a safe and effective treatment for the hepatic metastatic uveal melanoma, especially for patients with a hepatic tumor burden <25%.
Identifiants
pubmed: 34034537
doi: 10.1177/02841851211019808
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Melphalan
Q41OR9510P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM